Moderna presented 5-year melanoma data at ASCO 2026
The combination of intismeran autogene and KEYTRUDA showed sustained improvement in relapse-free survival and distant metastasis-free survival compared with KEYTRUDA alone.
See the latest news and media coverage for Moderna. We track all announcements, press releases, and industry mentions in real time, all in one place.
mRNA therapeutics and vaccine developer
modernatx.comLast updated
In short: Moderna advanced its pipeline with the first European approval for a combo flu-COVID shot and positive FDA advisory backing for its flu vaccine.
The combination of intismeran autogene and KEYTRUDA showed sustained improvement in relapse-free survival and distant metastasis-free survival compared with KEYTRUDA alone.
The New England Journal of Medicine publishes safety and efficacy data from study P304 in adults aged 50+.
Vertex terminates Phase 1/2 study of VX-522 due to tolerability issues. No broader portfolio impact; learnings inform future efforts.
Executive team discusses financial performance and late-stage pipeline milestones in IR Insights video. Plans include 10% revenue growth and expense reductions.
The U.S. Department of Justice has told the Federal Circuit that multibillion-dollar patent infringement litigation should be directed at the government, instead of Moderna, for...
Moderna stock drops 6% after a 39% rally as FDA flu vaccine news and Germany facility talks lift outlook.
Welcome to another installment of This Week at FDA, your weekly source for updates - big and small - on FDA, drug and medical device...
The U.S. Food and Drug Administration's advisers on Thursday backed approval of Moderna's flu vacci...
Track Moderna and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Moderna and other trending companies.